From Seekingalpha · Equity Eagle · · 40s
Stoke Therapeutics FDA Win Boosts Market Hopes
FDA approval for zorevunersen's cognition endpoint could reshape Dravet syndrome treatment outlook.
In brief
FDA approval for zorevunersen's cognition endpoint could reshape Dravet syndrome treatment outlook. Stoke Therapeutics' FDA acceptance of cognition/behavior endpoint for zorevunersen reduces regulatory risk for Dravet syndrome therapy. Originally reported by Seekingalpha.
FDA Cognition Endpoint Approval
The FDA accepted a cognition/behavior endpoint for zorevunersen, potentially the first disease-modifying Dravet syndrome therapy.
“The FDA’s acceptance of a cognition/behavior endpoint for EMPEROR reduces regulatory risk and differentiates zorevunersen from symptomatic competitors”
Cash Runway and Share Sale
Stoke Therapeutics has $420M cash and completed a $65.7M share sale at a premium to market, extending cash runway to early 2028.
2027 Readout Probability
Current valuation implies only a 30, 40% probability of EMPEROR success, offering asymmetric risk/reward ahead of the 2027 catalyst.
The big picture
Stoke Therapeutics' FDA acceptance of cognition/behavior endpoint for zorevunersen reduces regulatory risk for Dravet syndrome therapy.
